Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04318080
Title Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Acronym TIRHOL
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors BeiGene
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS


No variant requirements are available.